Avelox
(Moxifloxacin)ApprovedSmall molecule
BayerMoxifloxacin is an antibiotic used to treat bacterial infections, including respiratory infections, skin infections, and eye infections. It works by killing bacteria that cause these infections.[2] Avelox is currently approved and in use across 67 indications[4].[1]
Avelox is one of 1194 small molecule programs targeting Cellulitis. It is currently in Approved.
67
Indications
410
Total Trials
13
Active Trials
1,193
Competitors
5
FDA Applications
NDA/BLA/ANDA regulatory filings
2
Patents
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 64 indications
Competition
Competitive Landscape
2828 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Avelox
BayerApproved
Tykerb
GSKPreclinical
Prolia
AmgenPreclinical
Megace
Bristol-Myers SquibbPreclinical
Nubain
AAultman Health Foundation
Preclinical
Feraheme
AAzurity Pharmaceuticals
Preclinical
Systemic Therapy
Bristol-Myers SquibbPreclinical
Recombinant Human Endostatin
PPeking University Third Hospital
Preclinical
Conventional Chemotherapy
SShanghai Jiao Tong University School of Medicine
Preclinical
Tetracycline Hydrochloride
EEuropean Organisation for Research and Treatment of Cancer - EORTC
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Cardiac Repolarization24 trials
Show 21 more trials
Study to Evaluate The Effect Of Sertraline on the Cardiac Repolarization in Healthy Subjects
Completed·PPfizer's Upjohn has merged with Mylan to form Viatris Inc.·Phase 1·NCT02651623·54 enrolled
Heart11 trials
Show 8 more trials
Cardiac10 trials
Show 7 more trials
ART7 trials
Show 4 more trials
Adult6 trials
66 more indications
CAR6 trials
Study to Evaluate the Effect of Ha44 Gel on the Electrocardiogram in Healthy Volunteers
Completed·—·Phase 1·NCT01518699·57 enrolled
Show 3 more trials
A Study to Assess Electrocardiogram Results in Healthy Volunteers Receiving Canagliflozin (JNJ-28431754)
Completed·
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 1·NCT01787357·60 enrolled
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 1·NCT01787357·60 enrolledOral6 trials
Show 3 more trials
Bacterial Pneumonia5 trials
Single Dose4 trials
Pulmonary Tuberculosis4 trials
Short-course Regimens for the Treatment of Pulmonary Tuberculosis
Active, not recruiting·CCenters for Disease Control and Prevention·Phase 2/3·NCT05766267·288 enrolled
Early Bactericidal Activity of Linezolid, Gatifloxacin, Levofloxacin, Isoniazid (INH) and Moxifloxacin in HIV Negative Adults With Initial Episodes of Sputum Smear-Positive Pulmonary Tuberculosis
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1/2·NCT00396084·70 enrolled
TED4 trials
Tuberculosis4 trials
Innovating Shorter, All- Oral, Precised, Individualized Treatment Regimen for Rifampicin Resistant Tuberculosis：Contezolid, Delamanid and Bedaquiline Cohort
Active, not recruiting·—·Phase 3·NCT06081361·186 enrolled
Sitafloxacin-containing Regimens for Shortening Tuberculosis Treatment
Not yet recruiting·FFirst Affiliated Hospital of Zhejiang University·Phase 3·NCT05454345·620 enrolled
Show 1 more trial
Pneumonia4 trials
The Optimization of Mycoplasm Pneumonia Antibiotic Therapy
Completed·—·N/A·NCT01259141·208 enrolled
Efficacy and Safety Trial to Assess Moxifloxacin in Treating Community-Acquired Pneumonia (CAP) With Aspiration Factors
Unknown status·—·Phase 4·NCT00752947·186 enrolled
ALS4 trials
Show 1 more trial
Female4 trials
ESS3 trials
Women3 trials
Adult Subject3 trials
Function3 trials
Double-blind3 trials
Phase 13 trials
Clinical Trial2 trials
Endophthalmitis2 trials
Antibiotic2 trials
Treatment2 trials
Improving Retreatment Success (IMPRESS)
Completed·CCentre for the AIDS Programme of Research in South Africa·Phase 1/2·NCT02114684·197 enrolled
Concentration2 trials
Pelvic Inflammatory Disease2 trials
TIA2 trials
Schizophrenia2 trials
Complicated Intra-abdominal Infections2 trials
Celecoxib1 trial
Smokers1 trial
Appendicitis1 trial
Chronic Periodontitis1 trial
Mycobacterium1 trial
Treatment of Mycobacterium Xenopi Pulmonary Infection
Completed·—·Phase 3·NCT01298336·92 enrolled
Second-line Treatment1 trial
Quality of Life1 trial
Safety and Efficacy1 trial
Cystic Fibrosis1 trial
Efficacy and Safety1 trial
Absorption1 trial
Efficacy1 trial
NAC1 trial
Randomized1 trial
Long QT Syndrome1 trial
Blood Pressure1 trial
Helicobacter Pylori Infection1 trial
Empagliflozin1 trial
Azithromycin1 trial
Fluoroquinolone1 trial
Type 1 Diabetes1 trial
Effect of Glucose on QTc Interval in Type 1 Diabetes
Completed·—·Phase 1·NCT01984827·24 enrolled
Pregnancy1 trial
Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)··NCT00042289·1,578 enrolled
MPA1 trial
Pulmonary TB1 trial
Parkinson's Disease1 trial
Infection1 trial
Drug-Resistant Tuberculosis1 trial
Unspecified21 trials
Show 18 more trials
Regulatory
FDA Approval Timeline[5]
Dec 10, 1999
AVELOX
NDA NDA021085
Nov 30, 2001
AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER
NDA NDA021277
Apr 15, 2003
VIGAMOX
NDA NDA021598
Nov 19, 2010
MOXEZA
NDA NDA022428
Apr 3, 2015
MOXIFLOXACIN HYDROCHLORIDE
NDA NDA205572
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Avelox drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Moxifloxacin. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]FDA Orange Book — Patent and exclusivity data for Avelox. U.S. Food & Drug Administration.
- [7]